Global regulatory scale Leverage Validant’s integration into ELIQUENT Life Sciences to position cross-border regulatory strategy offerings, appealing to multinational life sciences firms seeking coordinated global compliance across pharma, biologics, devices and diagnostics.

Executive leadership updates Target contacts at pharmaceutical and medical device companies following recent leadership hires (CEO Tim Dietlin in May 2023 and Partner Joseph Jimenez in Oct 2023) as entry points for strategic regulatory modernization and growth initiatives.

Acquisition-driven growth Highlight opportunities with clients impacted by the Validant group’s acquisitions (COS, Oriel STAT A MATRIX, IDEC) to offer integrated service streams that consolidate COA, device regulation, and regional regulatory consulting under one umbrella.

Mid-market potential Position Validant’s revenue scale and mid-market footprint (51-200 employees, $100M-$250M revenue) as a compelling alternative to larger CROs for mid-sized drug, device, and combination product programs seeking hands-on regulatory execution and quality assurance.

Lifecycle enablement Promote end-to-end lifecycle regulatory support from preclinical through manufacturing and distribution, emphasizing risk-based quality, compliance optimization, and faster market access to attract developers aiming to accelerate product lifecycle outcomes.